Limits...
The use of amnion-derived cellular cytokine solution (ACCS) in accelerating closure of interstices in explanted meshed human skin grafts.

Uberti MG, Ko F, Pierpont YN, Johnson EL, Wright TE, Smith CA, Robson MC, Payne WG - Eplasty (2009)

Bottom Line: Serial wound tracings of unepithelialized interstitial wound areas were compared over time.Two different preparations of amnion-derived cellular cytokine solution were also compared with one another, one containing animal components and the other free of animal components.There were no statistical differences among the 3 amnion-derived cellular cytokine solution-treated groups.

View Article: PubMed Central - PubMed

Affiliation: Institute for Tissue Regeneration, Repair, and Rehabilitation, Bay Pines VAHCS, Bay Pines, FL, USA.

ABSTRACT

Unlabelled: Meshed, split-thickness skin grafts, especially when required to be widely spread, do not obtain immediate biologic closure. In patients with burns that cover a large percentage of the body surface area, this leaves the patient at risk for metabolic problems and life-threatening infection.

Objective: The purpose of this study was to determine whether amnion-derived cellular cytokine solution could improve epithelialization kinetics and accelerate closure of meshed skin graft interstices.

Methods: Human meshed, split-thickness skin grafts were explanted to athymic "nude" rats and treated with 3 different regimens of amnion-derived cellular cytokine solution (groups I, II, and III) or normal saline (group IV) as a control. Serial wound tracings of unepithelialized interstitial wound areas were compared over time. Two different preparations of amnion-derived cellular cytokine solution were also compared with one another, one containing animal components and the other free of animal components.

Results: Only 67.03% of interstices in control animals closed by day 9. This compared with 92.2% closure for group I, 83.72% for group II, and 90.64% for group III. Interstices in all 3 groups treated with amnion-derived cellular cytokine solution (with or without animal-derived components) closed faster statistically than in the control animals (P < .05). There were no statistical differences among the 3 amnion-derived cellular cytokine solution-treated groups.

Conclusions: These data suggest that epithelialization kinetics and interstitial closure of meshed skin grafts can be accelerated with the use of amnion-derived cellular cytokine solution, a physiologic cocktail of cytokines, and provide support for a future clinical trial.

No MeSH data available.


Related in: MedlinePlus

A 30-cm2 defect on the dorsum of a “nude” rat.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2664608&req=5

Figure 1: A 30-cm2 defect on the dorsum of a “nude” rat.

Mentions: With the use of strict aseptic techniques and working within a unidirectional airflow biologic hood, the rats were anesthetized with intraperitoneal pentobarbital (Nembutal) at a dose of 35 mg/kg body weight. After the dorsal skin was treated with povidone-iodine solution, a standardized full-thickness area (30-cm2) of skin and panniculus carnosa were excised (Fig 1). The meshed skin graft was pinned to a corkboard that had a cutout area the same size as the wound that was inflicted to each animal.6,7 The graft was then spread to the greatest degree possible in an effort to maximize the extent of graft interstices. This maximally spread meshed graft was then grafted to the wound on the animal and fixed with staples to the surrounding wound edges (Fig 2). The grafts were treated with the test solutions by pumping the solutions from a pump actuator at a rate of 0.01 mL/cm2 of graft. The grafts were dressed with N-Terface nonadherent gauze (Winfield Laboratories, Inc, Richardson, Tex) and covered with an 8-ply gauze dressing.


The use of amnion-derived cellular cytokine solution (ACCS) in accelerating closure of interstices in explanted meshed human skin grafts.

Uberti MG, Ko F, Pierpont YN, Johnson EL, Wright TE, Smith CA, Robson MC, Payne WG - Eplasty (2009)

A 30-cm2 defect on the dorsum of a “nude” rat.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2664608&req=5

Figure 1: A 30-cm2 defect on the dorsum of a “nude” rat.
Mentions: With the use of strict aseptic techniques and working within a unidirectional airflow biologic hood, the rats were anesthetized with intraperitoneal pentobarbital (Nembutal) at a dose of 35 mg/kg body weight. After the dorsal skin was treated with povidone-iodine solution, a standardized full-thickness area (30-cm2) of skin and panniculus carnosa were excised (Fig 1). The meshed skin graft was pinned to a corkboard that had a cutout area the same size as the wound that was inflicted to each animal.6,7 The graft was then spread to the greatest degree possible in an effort to maximize the extent of graft interstices. This maximally spread meshed graft was then grafted to the wound on the animal and fixed with staples to the surrounding wound edges (Fig 2). The grafts were treated with the test solutions by pumping the solutions from a pump actuator at a rate of 0.01 mL/cm2 of graft. The grafts were dressed with N-Terface nonadherent gauze (Winfield Laboratories, Inc, Richardson, Tex) and covered with an 8-ply gauze dressing.

Bottom Line: Serial wound tracings of unepithelialized interstitial wound areas were compared over time.Two different preparations of amnion-derived cellular cytokine solution were also compared with one another, one containing animal components and the other free of animal components.There were no statistical differences among the 3 amnion-derived cellular cytokine solution-treated groups.

View Article: PubMed Central - PubMed

Affiliation: Institute for Tissue Regeneration, Repair, and Rehabilitation, Bay Pines VAHCS, Bay Pines, FL, USA.

ABSTRACT

Unlabelled: Meshed, split-thickness skin grafts, especially when required to be widely spread, do not obtain immediate biologic closure. In patients with burns that cover a large percentage of the body surface area, this leaves the patient at risk for metabolic problems and life-threatening infection.

Objective: The purpose of this study was to determine whether amnion-derived cellular cytokine solution could improve epithelialization kinetics and accelerate closure of meshed skin graft interstices.

Methods: Human meshed, split-thickness skin grafts were explanted to athymic "nude" rats and treated with 3 different regimens of amnion-derived cellular cytokine solution (groups I, II, and III) or normal saline (group IV) as a control. Serial wound tracings of unepithelialized interstitial wound areas were compared over time. Two different preparations of amnion-derived cellular cytokine solution were also compared with one another, one containing animal components and the other free of animal components.

Results: Only 67.03% of interstices in control animals closed by day 9. This compared with 92.2% closure for group I, 83.72% for group II, and 90.64% for group III. Interstices in all 3 groups treated with amnion-derived cellular cytokine solution (with or without animal-derived components) closed faster statistically than in the control animals (P < .05). There were no statistical differences among the 3 amnion-derived cellular cytokine solution-treated groups.

Conclusions: These data suggest that epithelialization kinetics and interstitial closure of meshed skin grafts can be accelerated with the use of amnion-derived cellular cytokine solution, a physiologic cocktail of cytokines, and provide support for a future clinical trial.

No MeSH data available.


Related in: MedlinePlus